Research Progress of 64Cu-ATSM Drugs Labeled with Metal Positron Nuclide
LIAO Guangxing, LI Ning, HE Zhengzhong, XIAO Guoyou
Department of Nuclear Medicine, Guangxi Medical University Affiated Tumor Hospital, Guangxi Clinical Research Center of
Imaging Medicine, Guangxi Key Clinical Specialty (Department of Nuclear Medicine and Department of Medical Image),
Discipline of Advantage Cultivation (Department of Medical Image), Guangxi Medical University Affiated Tumor Hospital,
Nanning Guangxi 530021, China
Abstract：The development and application of positron nuclides and their labeled radiopharmaceuticals for imaging diagnosis
and disease treatment provide a strong foundation for the development of molecular imaging and nuclear medicine, and improve
the level of medical diagnosis and treatment. This article mainly focused on the chemical synthesis and quality control of 64Cu-
ATSM drugs labeled with metal positron nuclide 64Cu produced by medical cyclotrons, the basic research of 64Cu-ATSM in
hypoxia imaging at domestic and foreign country, the diagnosis of tumor disease, the application value of radiotherapy for
glioma, the formulation of tumor radiotherapy plan and prognosis evaluation were reviewed. 64Cu-ATSM drug has excellent
physical, chemical and biological properties. With the continuous deepening of its basic research and extensive clinical use, largescale
medical molecular imaging equipment PET/CT and PET/MR will play a greater role in disease diagnosis and treatment, it
promotes the development of precision medicine.
廖光星，李宁，何正中，肖国有. 金属正电子核素标记的64Cu-ATSM药物研究进展[J]. 中国医疗设备, 2021, 36(8): 165-169.
LIAO Guangxing, LI Ning, HE Zhengzhong, XIAO Guoyou. Research Progress of 64Cu-ATSM Drugs Labeled with Metal Positron Nuclide. China Medical Devices, 2021, 36(8): 165-169.
